Mechanism of Action

Mechanism of Action

Immunogenic Cell Death and DAMPs: How EBC-46 (Tigilanol Tiglate) Recruits the Immune System Against Tumours

How EBC-46 / tigilanol tiglate triggers immunogenic cell death and releases damage-associated molecular patterns to recruit innate and adaptive anti-tumour immunity.

Mechanism of Action

Caspase-Mediated Apoptosis in EBC-46 Tumour Cell Death: The Executioner Pathway

How caspase-3 and caspase-9 activation contributes to programmed tumour cell death following tigilanol tiglate exposure, and what cell-line studies have observed downstream.

Mechanism of Action

Autophagy and EBC-46: How Tigilanol Tiglate Engages the Cellular Recycling Pathway

An overview of the autophagic cell death pathway, why diacylglycerol mimics like tigilanol tiglate may engage it, and where the mechanistic evidence currently stands for EBC-46.

Mechanism of Action

Calcium Signalling and EBC-46: ER Stress and Intracellular Calcium in Tumour Cell Death

How calcium release from the endoplasmic reticulum, PKC-delta activation, and mitochondrial calcium uptake contribute to the published mechanism of action of EBC-46 tigilanol tiglate.

Mechanism of Action

Neutrophil Recruitment After EBC-46 Injection: How Tigilanol Tiglate Mobilises Innate Immunity

Published preclinical data shows rapid neutrophil infiltration after intratumoral tigilanol tiglate. Here is what that tells us about EBC-46’s innate immune mechanism.

EBC-46

Cytolytic Cascade: How EBC-46 Triggers Tumour Cell Membrane Disruption

The cytolytic cascade triggered by tigilanol tiglate — PKC activation, membrane destabilisation, and necrotic cell death — explained from the peer-reviewed literature.

Mechanism of Action

Endothelial Cell Permeability and EBC-46: How Tigilanol Tiglate Disrupts Tumour Vascular Integrity

Examining the published research on how EBC-46 increases endothelial cell permeability, contributing to rapid vascular disruption in tumour microenvironments.

Mechanism of Action

Mitochondrial Membrane Potential and EBC-46: How Tigilanol Tiglate May Influence Cellular Energy Pathways

Exploring the emerging research on how tigilanol tiglate's PKC-delta activation may affect mitochondrial membrane potential and downstream cellular energy dynamics.

Mechanism of Action

Calcium-Dependent PKC Activation by EBC-46: Why the C1 Domain Matters

Examining how EBC-46 binds the C1 domain of protein kinase C isoforms and why calcium-dependent activation drives rapid tumour response in preclinical models.

Mechanism of Action

VEGF Suppression and EBC-46: How Tigilanol Tiglate Affects Tumour Angiogenesis

Beyond its direct vascular disruption effect, tigilanol tiglate may suppress VEGF signalling — a mechanism that could explain the durability of tumour responses observed in EBC-46 preclinical research.

Mechanism of Action

How EBC-46 Disrupts Tumour Vasculature: The PKC-Delta to Endothelial-Damage Cascade

A plain-language walk through the current mechanistic model for tigilanol tiglate — from PKC activation at the cell membrane to the localised vascular collapse seen in preclinical work.

Mechanism of Action

How EBC-46 Works: PKC-Delta Activation and Vascular Disruption Explained

A detailed look at tigilanol tiglate's dual mechanism of action — PKC-delta activation and tumour vascular disruption — and what it means for supplement consumers.